Teitur Trophics has raised €28 million (about $29.7 million) to advance its lead candidate, TT-P34, into a Phase 1b clinical trial as a possible treatment for Parkinson’s and other neurodegenerative diseases. “There is a pressing need for new therapies for neurodegenerative diseases which have a detrimental impact on…
News
BlueRock Therapeutics will use digital health technologies from Rune Labs and Emerald Innovations to remotely monitor a subset of Parkinson’s disease patients in an observational clinical study. The goal of the two-year study (NCT05363046) is to shed light on patients’ daily experiences with the neurodegenerative disease via…
Newron Pharmaceuticals and Zambon Pharma have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease. Xadago is widely approved as an add-on treatment to help manage Parkinson’s off episodes, or periods when symptoms…
Cure Parkinson’s and the Van Andel Institute (VAI) will continue to support a global program that seeks to develop disease-modifying therapies for Parkinson’s — to which the two donated $4.5 million in 2020. Now, the U.K. charity and the Michigan-based research institute have renewed their previous funding agreement…
Eating a tailored prebiotic fiber bar — meant to help nourish good bacteria in the gut — for 10 days boosted the abundance of anti-inflammatory bacteria in the microbiome of people with Parkinson’s disease, a proof-of-concept clinical trial reported. These effects were associated with better intestinal health and protection…
Olatec Therapeutics has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further investigate its lead oral candidate, dapansutrile, in animal models of Parkinson’s disease. Such preclinical work will be conducted in collaboration with researchers at the Medical University of Innsbruck in Austria…
Overproduction of toxic forms of the alpha-synuclein protein — a Parkinson’s disease hallmark — in the vagus nerve, the longest nerve connecting the brain to the intestines and other key organs, disrupts the autonomic nervous system prior to motor symptom onset, a study in a new rat model reported. The…
The sixth annual Parkinson’s Expo, a free and educational conference covering a range of topics related to Parkinson’s disease, is set for Saturday, March 25, in Palmetto, Florida and virtually. Hosted by the Neuro Challenge Foundation and designed with input from the Parkinson’s community, the event is intended to…
Researchers have found a genetic association between Parkinson’s disease and melanoma, a type of skin cancer, and prostate cancer. Data also showed that Parkinson’s genetic risk factors are linked to an increased risk of breast cancer and lower risk of ovarian cancer. “Our results suggest the importance of shared genetic…
Inbrija (levodopa inhalation powder), an approved therapy for off episodes in Parkinson’s patients on certain standard levodopa-based treatments, is now available in Spain. Developed by Acorda Therapeutics, the therapy was approved in the U.S. in 2018 and for the European Union in 2019. In Spain and Germany — where…
Recent Posts
- Looking back at the changing roles and relationships in Parkinson’s
- Lab-made small molecule may help slow brain disease progression
- New report shows Parkinson’s costs surpass $82 billion in US in 2024
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China